title: Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
abstract: OBJECTIVE
  The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community.
  
  
  METHODS
  Patients receiving first- or second-line single-agent sorafenib between January 2008 and December 2010 were eligible. Retrospective data collection started in 2012 and covers at least 1-year follow-up. The primary end point was overall survival (OS).
  
  
  RESULTS
  Median OS was 17.2 months (95% CI: 15.5-19.6): 19.9 months (95% CI: 15.9-25.3) in patients treated with first-line sorafenib and 16.3 months (95% CI: 13.1-18.2) with second-line sorafenib. Overall median (95% CI) progression-free survival was 5.9 months (95% CI: 4.9-6.7): 6.6 (95% CI: 4.9-9.3) and 5.3 months (95% CI: 4.3-6.0) in first- and second-line patients, respectively.
  
  
  CONCLUSIONS
  The efficacy and safety of sorafenib in routine community practice was generally good, especially in relation to OS in patients treated in the second line, where results were similar to those seen in recent prospective clinical trials.
authors.affiliation: S.C. Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133 Milano, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
authors.forename: Lisa
authors.initials: L
authors.lastname: Derosa
authors.forename: Angela
authors.initials: A
authors.lastname: Gernone
authors.forename: Franco
authors.initials: F
authors.lastname: Morelli
authors.forename: Teodoro
authors.initials: T
authors.lastname: Sava
authors.forename: Fable
authors.initials: F
authors.lastname: Zustovich
authors.forename: Ugo
authors.initials: U
authors.lastname: De Giorgi
authors.forename: Vittorio
authors.initials: V
authors.lastname: Ferrari
authors.forename: Roberto
authors.initials: R
authors.lastname: Sabbatini
authors.forename: Donatello
authors.initials: D
authors.lastname: Gasparro
authors.forename: Alessandra
authors.initials: A
authors.lastname: Felici
authors.forename: Luciano
authors.initials: L
authors.lastname: Burattini
authors.forename: Nicola
authors.initials: N
authors.lastname: Calvani
authors.forename: Giovanni
authors.initials: G
authors.lastname: Lo Re
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Banna
authors.forename: Maria
authors.initials: M
authors.lastname: Pia Brizzi
authors.forename: Mimma
authors.initials: M
authors.lastname: Rizzo
authors.forename: Libero
authors.initials: L
authors.lastname: Ciuffreda
authors.forename: Roberto
authors.initials: R
authors.lastname: Iacovelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Ferraù
authors.forename: Eleonora
authors.initials: E
authors.lastname: Taibi
authors.forename: Sergio
authors.initials: S
authors.lastname: Bracarda
authors.forename: Camillo
authors.initials: C
authors.lastname: Porta
authors.forename: Enzo
authors.initials: E
authors.lastname: Galligioni
authors.forename: Antonio
authors.initials: A
authors.lastname: Contu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
keywords: community practice; renal cell carcinoma; second-line treatment; sorafenib; targeted agents; tyrosine kinase inhibitors